[ARCHIVE]2026-06-18T18:02:33.041723+00:00

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions - Immix Biopharma (NASDAQ:IMMX)

BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.

Deep analysis unavailable for this source.